By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Investment bank Wedbush Securities has initiated coverage of Caliper Life Sciences with an 'Outperform' rating and a 12-month price target of $9.

Wedbush analyst Zarak Kurshid cited Caliper's products for the sequencing and diagnostic markets as key drivers for the firm. He also said that recent divestitures provide a "cleaner story" as the firm moves toward sustainable profitability.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.